|Solubility:||DMSO up to 10 mM|
|Storage:||Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.|
NSC636819 is a cell permeable and selective novel active-site KDM4A/KDM4B inhibitor with IC50 ~6.4 μM for KDM4A and 9.3 μM for KDM4B. It inhibits histone demethylase activity on H3K9me3 and induces apoptosis in LNCaP prostate cancer cells in vitro. It also negatively regulates androgen-responsive genes. The overexpression of KDM4A/KDM4B in prostate cancer and their association with androgen receptor suggest that KDM4A/KDM4B are potential progression factors for prostate cancer.
How to Use:
In vitro: NSC636819 was used at 10 µM final concentration in vitro and in cellular assays.
In vivo: n/a
- 1. Chu CH, et al. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor. (2014) J Med Chem. 57(14):5975-85.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.